Coronavirus (829) Weekly update no.14 - Evidence Aid COVID-19 project

16 July, 2020

Dear Friends (with apologies for any cross-posting),

Here is the 14th weekly update on our COVID-19 project.

Highlights: With the WHO warning last week that the COVID-19 pandemic is still accelerating, demand for Evidence Aid's online summaries of high-quality evidence remains high. This week, a surge in digital engagement from Spanish-speaking South America has resulted in our highest ever number of web users in a single day (5,050).

Evidence Aid COVID-19 Weekly Bulletin

Report covering 7 days to 14th July 2020 - https://evidenceaid.org/evidence/coronavirus-covid-19/

Systematic review summaries

337 summaries on the website in total (5 added in this period); 97 summaries in progress;

Translations

333 in Arabic; 332 in Chinese (simplified); 332 in Chinese (traditional); 334 in French; 32 in Italian; 332 in Portuguese; 334 in Spanish;

Literature searches

0 search completed in this period; 1 search in progress;

Volunteers

A total of 63 amazing volunteers (39 summary writers; 10 screeners; 14 information specialists/librarians) from 15 countries;

Digital engagement

25,726 people have used the Evidence website in this 7-day period for a total of 139,424 users since we started collecting data in mid-March. Some 60% of our audience this week came from Spanish-speaking South American countries following social media promotion of our Spanish-language resources. Our top ten countries this week were: Mexico, El Salvador, Egypt, Chile, India, South Africa, Algeria, United States, Saudi Arabia and Iraq.

The summaries with most views this week were D-dimer levels associated with severity of COVID-19<https://eur01.safelinks.protection.outlook.com/> and N95 respirators and surgical masks<https://eur01.safelinks.protection.outlook.com/> (both in Arabic), followed by Rehabilitation and early mobilisation in the critical patient<https://eur01.safelinks.protection.outlook.com/> (in Spanish).

Partnerships

We are grateful to Twitter, who have granted us substantial pro-bono advertising. Among others, we are collaborating with WHO, Public Health England, PAHO, Queen's University Belfast, Health and Social Care Northern Ireland, Cochrane, Campbell, Translators Without Borders, Global Evidence Synthesis Initiative, the Irish Global Health Network, Health Service Executive Ireland, McMaster University (COVID-END) and Oxford PharmaGenesis. Evidence Aid are supported by H2H, with funding from UK Aid, and by a core grant from Oxford PharmaGenesis.

Best wishes,

Ben

Ben Heaven Taylor

Chief Executive Officer

Email: bhtaylor@evidenceaid.org<mailto:bhtaylor@evidenceaid.org> | skype: live:ben_taylor45 |Phone: +44 (0)7880 635014 |Web: www.evidenceaid.org<http://www.evidenceaid.org/> | Twitter @EvidenceAid

Championing evidence-based humanitarian action

Support our activities by donating here https://eur01.safelinks.protection.outlook.com/

For the Evidence Aid resources on COVID-19 (Coronavirus), visit https://www.evidenceaid.org/coronavirus-resources/

HIFA profile: Ben Heaven Taylor is Chief Executive Officer at Evidence Aid, UK: Championing evidence-based humanitarian action. www.evidenceaid.org @EvidenceAid Email: bhtaylor AT evidenceaid.org